ipilimumab,nivolumab,durvalumab,vinorelbine,paclitaxel,carboplatin,cisplatin,gemcitabine,docetaxel,pemetrexed
bms,astrazeneca
['durva', 'aegean']
interim analysis of efs from aegean shows durvalumab pre/post surgery significantly improves pfs (hr 0.68) over placebo with 1y efs rate 73.4% vs 64.5% and 2y efs rate 63.3% vs 52.4% (efs only 32% mature). very early split of the curves with clear separation. #aacr23 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast #ITYSL #HereWeGo